RFK, Jr., puts psychedelics on fast track to FDA review and approval
The U.S. Food and Drug Administration is seeking to accelerate the review process for three companies that are studying psilocybin and an MDMA-like drug as treatments for depression and PTSD
- U.S. FDA plans ultra-fast review of three psychedelic drugs following Trump directive CTV News —
- US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive South China Morning Post —
- FDA grants quick review for 3 psychedelic drug trials NBC News —
- FDA fast-tracks psychedelic drug research following Trump executive order CNBC —
- FDA plans fast review of 3 psychedelic drugs following Trump directive Boston Globe —